Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma

Heather Magnan, Christine M. Goodbody, Elyn Riedel, Christine A. Pratilas, Leonard H. Wexler, Alexander J. Chou

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Background: Outcomes for patients with metastatic Ewing sarcoma (ES) remain poor. We investigated whether the intensification of ifosfamide improved survival for patients with metastatic ES. Procedure: We conducted a retrospective chart review of 30 patients with metastatic ES treated with the MSKCC "EFT regimen." The regimen included an intensification of ifosfamide dosing from 1,800mg/m2/day × 5 days per cycle to 2,800mg/m2/day × 5 days per cycle. Results: Twenty six of the 30 patients completed planned chemotherapy. Two patients experienced disease progression during therapy. There were no toxic deaths. One patient developed secondary leukemia. The 4-year event free survival (EFS) was 27% and the overall survival (OS) was 39%. Conclusions: Intensification of ifosfamide was tolerated and did not increase toxicity in patients with metastatic ES. The intensification did not improve outcomes for these patients with metastatic disease. Pediatr Blood Cancer 2015;62:594-597.

Original languageEnglish (US)
Pages (from-to)594-597
Number of pages4
JournalPediatric Blood and Cancer
Issue number4
StatePublished - Apr 1 2015
Externally publishedYes


  • Chemotherapy
  • Ewing sarcoma
  • Outcomes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma'. Together they form a unique fingerprint.

Cite this